These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 36688491

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. L-Type amino acid transporter 1 (LAT1)-utilizing prodrugs are carrier-selective despite having low affinity for organic anion transporting polypeptides (OATPs).
    Huttunen J, Gynther M, Vellonen KS, Huttunen KM.
    Int J Pharm; 2019 Nov 25; 571():118714. PubMed ID: 31610281
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A selectively suppressing amino acid transporter: Sodium-coupled neutral amino acid transporter 2 inhibits cell growth and mammalian target of rapamycin complex 1 pathway in skeletal muscle cells.
    Zhang L, Duan Y, Guo Q, Wang W, Li F.
    Anim Nutr; 2020 Dec 25; 6(4):513-520. PubMed ID: 33364468
    [Abstract] [Full Text] [Related]

  • 6. L-type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain delivery.
    Puris E, Gynther M, Huttunen J, Auriola S, Huttunen KM.
    Eur J Pharm Sci; 2019 Mar 01; 129():99-109. PubMed ID: 30625368
    [Abstract] [Full Text] [Related]

  • 7. Enhanced small neutral but not branched chain amino acid transport after epigenetic sodium coupled neutral amino acid transporter-2 (SNAT2) cDNA expression in myoblasts.
    Pearson T, Wendowski O, Powell PP.
    J Cachexia Sarcopenia Muscle; 2021 Jun 01; 12(3):811-822. PubMed ID: 33982880
    [Abstract] [Full Text] [Related]

  • 8. Amino acid ester prodrugs conjugated to the α-carboxylic acid group do not display affinity for the L-type amino acid transporter 1 (LAT1).
    Rautio J, Kärkkäinen J, Huttunen KM, Gynther M.
    Eur J Pharm Sci; 2015 Jan 23; 66():36-40. PubMed ID: 25305508
    [Abstract] [Full Text] [Related]

  • 9. L-type amino acid transporter 1 utilizing prodrugs: How to achieve effective brain delivery and low systemic exposure of drugs.
    Puris E, Gynther M, Huttunen J, Petsalo A, Huttunen KM.
    J Control Release; 2017 Sep 10; 261():93-104. PubMed ID: 28662899
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. L-Type Amino Acid Transporter 1 (LAT1/Lat1)-Utilizing Prodrugs Can Improve the Delivery of Drugs into Neurons, Astrocytes and Microglia.
    Huttunen J, Peltokangas S, Gynther M, Natunen T, Hiltunen M, Auriola S, Ruponen M, Vellonen KS, Huttunen KM.
    Sci Rep; 2019 Sep 06; 9(1):12860. PubMed ID: 31492955
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Amino acid prodrugs of acyclovir as possible antiviral agents against ocular HSV-1 infections: interactions with the neutral and cationic amino acid transporter on the corneal epithelium.
    Anand BS, Katragadda S, Nashed YE, Mitra AK.
    Curr Eye Res; 2004 Sep 06; 29(2-3):153-66. PubMed ID: 15512962
    [Abstract] [Full Text] [Related]

  • 14. Putative transport mechanism and intracellular fate of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid in human prostate cancer.
    Okudaira H, Shikano N, Nishii R, Miyagi T, Yoshimoto M, Kobayashi M, Ohe K, Nakanishi T, Tamai I, Namiki M, Kawai K.
    J Nucl Med; 2011 May 06; 52(5):822-9. PubMed ID: 21536930
    [Abstract] [Full Text] [Related]

  • 15. Identification of a Na+-dependent cationic and neutral amino acid transporter, B(0,+), in human and rabbit cornea.
    Jain-Vakkalagadda B, Pal D, Gunda S, Nashed Y, Ganapathy V, Mitra AK.
    Mol Pharm; 2004 May 06; 1(5):338-46. PubMed ID: 16026003
    [Abstract] [Full Text] [Related]

  • 16. Functional characterization and molecular expression of large neutral amino acid transporter (LAT1) in human prostate cancer cells.
    Patel M, Dalvi P, Gokulgandhi M, Kesh S, Kohli T, Pal D, Mitra AK.
    Int J Pharm; 2013 Feb 25; 443(1-2):245-53. PubMed ID: 23270998
    [Abstract] [Full Text] [Related]

  • 17. Structural properties for selective and efficient l-type amino acid transporter 1 (LAT1) mediated cellular uptake.
    Kärkkäinen J, Gynther M, Kokkola T, Petsalo A, Auriola S, Lahtela-Kakkonen M, Laine K, Rautio J, Huttunen KM.
    Int J Pharm; 2018 Jun 10; 544(1):91-99. PubMed ID: 29669256
    [Abstract] [Full Text] [Related]

  • 18. Tyrosine-Chlorambucil Conjugates Facilitate Cellular Uptake through L-Type Amino Acid Transporter 1 (LAT1) in Human Breast Cancer Cell Line MCF-7.
    Pocasap P, Weerapreeyakul N, Timonen J, Järvinen J, Leppänen J, Kärkkäinen J, Rautio J.
    Int J Mol Sci; 2020 Mar 20; 21(6):. PubMed ID: 32244913
    [Abstract] [Full Text] [Related]

  • 19. Molecular characteristics supporting l-Type amino acid transporter 1 (LAT1)-mediated translocation.
    Kärkkäinen J, Laitinen T, Markowicz-Piasecka M, Montaser A, Lehtonen M, Rautio J, Gynther M, Poso A, Huttunen KM.
    Bioorg Chem; 2021 Jul 20; 112():104921. PubMed ID: 33933805
    [Abstract] [Full Text] [Related]

  • 20. The L-type amino acid transporter 1 enhances drug delivery to the mouse pancreatic beta cell line (MIN6).
    Tampio J, Montaser AB, Järvinen J, Lehtonen M, Jalkanen AJ, Reinisalo M, Kokkola T, Terasaki T, Laakso M, Rysä J, Kauppinen A, Huttunen KM.
    Eur J Pharm Sci; 2024 Dec 01; 203():106937. PubMed ID: 39419128
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.